Vertex Ventures HC
Vertex Ventures HC (VVHC) is a women-led, US-based healthcare venture capital firm investing in life science innovation worldwide. VVHC invests across biopharmaceuticals, medical devices and digital health, taking active board and portfolio roles from early/preclinical stages through commercial-stage companies. The firm operates from San Francisco and Boston and leverages a global Vertex network for cross-border business development, manufacturing and clinical collaboration.
Industries
Nr. of Employees
small (1-50)
Vertex Ventures HC
San Francisco: 76 South Park Street, San Francisco, CA 94107, United States
Portfolio
Developing ATX101, an ultra-sustained analgesic for post-surgical pain; Series D financing and IND/Phase 2b activity reported in 2025.
#Medtech / Biotech (post-surgical analgesia)
Developer of the MISHA Knee System (FDA cleared 2023); enrolling randomized controlled trial (MOTION RCT) as of 2025.
#Medtech (orthopedics, implantable shock absorber)
Developed an IOL-mounted long-term drug delivery platform for glaucoma; announced $75M Series D in June 2025 to support registrational Phase III trials.
#Ophthalmic biotech / drug-delivery
Developed a battery-free percutaneous sacral neuromodulation (pSNM) system for urgency urinary incontinence; reported 6-month pivotal trial results in 2025.
#Medtech / Bioelectronic medicine
Developing OBX-115, an engineered TIL cell therapy; reported Phase 1 safety and efficacy data in advanced melanoma (ASCO 2025).
#Biotech (engineered cell and gene therapies)
Developer of the Hydrus Microstent for glaucoma; multiple clinical trials and regulatory milestones reported; listed as an acquired/IPO outcome in portfolio.
#Medtech (ophthalmology, MIGS devices)
Developing ATX101, an ultra-sustained analgesic for post-surgical pain; Series D financing and IND/Phase 2b activity reported in 2025.
#Medtech / Biotech (post-surgical analgesia)
Developer of the MISHA Knee System (FDA cleared 2023); enrolling randomized controlled trial (MOTION RCT) as of 2025.
#Medtech (orthopedics, implantable shock absorber)
Developed an IOL-mounted long-term drug delivery platform for glaucoma; announced $75M Series D in June 2025 to support registrational Phase III trials.
#Ophthalmic biotech / drug-delivery
Developed a battery-free percutaneous sacral neuromodulation (pSNM) system for urgency urinary incontinence; reported 6-month pivotal trial results in 2025.
#Medtech / Bioelectronic medicine
Developing OBX-115, an engineered TIL cell therapy; reported Phase 1 safety and efficacy data in advanced melanoma (ASCO 2025).
#Biotech (engineered cell and gene therapies)
Developer of the Hydrus Microstent for glaucoma; multiple clinical trials and regulatory milestones reported; listed as an acquired/IPO outcome in portfolio.
#Medtech (ophthalmology, MIGS devices)